In the subgroup analyses with different medical histories, comparing the patients with/without previous AECI/ARB treatment or comorbidities (e.g., HTN, DM, CKD, CHD, DCM), there were no significant difference in the 6-month reduction of NT-proBNP and the improvement of LVEF (Appendix Fig. 4—subgroup analysis of comorbidity). The gene discussed is NPPB; the disease is chronic kidney disease.